Sumitomo Chemical India Ltd
Sumitomo Chemical India Ltd. (SCIL) is one of the leading players in the industry which has a balanced portfolio of technical as well as formulation products along with backward integration for some products. The Company is known for domestic marketing of proprietary products of its Japanese parent -Sumitomo Chemical Company Limited in agrochemicals, animal nutrition, and environmental health business segments. With the integration of Excel Crop Care Limited, the Company now has a strong portfolio of generics in addition to specialty products and a strong combined marketing network. With this integration, the Company has moved up several notches in the pecking order of the Indian crop protection industry. SCIL has also marked its presence in Africa and several other geographies of the world.[1] [2]
- Market Cap ₹ 23,053 Cr.
- Current Price ₹ 462
- High / Low ₹ 665 / 363
- Stock P/E 41.6
- Book Value ₹ 67.8
- Dividend Yield 0.26 %
- ROCE 23.5 %
- ROE 17.7 %
- Face Value ₹ 10.0
Pros
- Company is almost debt free.
- Company has been maintaining a healthy dividend payout of 34.5%
Cons
- The company has delivered a poor sales growth of 3.81% over past five years.
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Quarterly Results
Standalone Figures in Rs. Crores / View Consolidated
Profit & Loss
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 671 | 724 | 799 | 1,911 | 2,223 | 2,423 | 2,643 | 3,060 | 3,511 | 2,833 | 3,090 | 3,186 | |
| 614 | 635 | 698 | 1,691 | 1,932 | 2,088 | 2,155 | 2,458 | 2,843 | 2,358 | 2,467 | 2,521 | |
| Operating Profit | 57 | 89 | 101 | 219 | 291 | 335 | 488 | 603 | 668 | 474 | 623 | 665 |
| OPM % | 8% | 12% | 13% | 11% | 13% | 14% | 18% | 20% | 19% | 17% | 20% | 21% |
| 8 | 26 | 10 | 31 | -0 | -20 | 19 | 36 | 45 | 96 | 119 | 131 | |
| Interest | 1 | 1 | 1 | 5 | 5 | 7 | 7 | 8 | 6 | 5 | 6 | 7 |
| Depreciation | 6 | 7 | 7 | 24 | 28 | 41 | 47 | 45 | 52 | 61 | 63 | 63 |
| Profit before tax | 58 | 107 | 103 | 221 | 258 | 267 | 453 | 586 | 655 | 503 | 674 | 727 |
| Tax % | 40% | 40% | 40% | 34% | 35% | 23% | 24% | 26% | 23% | 27% | 26% | 25% |
| 35 | 65 | 62 | 145 | 167 | 206 | 345 | 434 | 503 | 370 | 502 | 543 | |
| EPS in Rs | 4.12 | 6.92 | 8.69 | 10.09 | 7.41 | 10.06 | 10.88 | |||||
| Dividend Payout % | 0% | 0% | 0% | 0% | 38% | 18% | 12% | 12% | 12% | 80% | 12% | 12% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | 16% |
| 5 Years: | 4% |
| 3 Years: | -3% |
| TTM: | 3% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 24% |
| 5 Years: | 10% |
| 3 Years: | 3% |
| TTM: | 10% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | 4% |
| 3 Years: | 4% |
| 1 Year: | -7% |
| Return on Equity | |
|---|---|
| 10 Years: | 20% |
| 5 Years: | 20% |
| 3 Years: | 17% |
| Last Year: | 18% |
Balance Sheet
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 233 | 233 | 275 | 275 | 275 | 499 | 499 | 499 | 499 | 499 | 499 | 499 |
| Reserves | -2 | 63 | 360 | 665 | 761 | 710 | 1,029 | 1,425 | 1,881 | 1,941 | 2,397 | 2,885 |
| 0 | 0 | 0 | 10 | 20 | 36 | 33 | 38 | 34 | 25 | 45 | 53 | |
| 234 | 280 | 288 | 695 | 791 | 848 | 1,097 | 1,047 | 955 | 822 | 988 | 997 | |
| Total Liabilities | 466 | 576 | 922 | 1,644 | 1,846 | 2,093 | 2,658 | 3,009 | 3,368 | 3,287 | 3,930 | 4,434 |
| 51 | 52 | 53 | 267 | 279 | 319 | 309 | 390 | 430 | 489 | 482 | 516 | |
| CWIP | 0 | 1 | 7 | 9 | 8 | 10 | 14 | 35 | 71 | 23 | 28 | 3 |
| Investments | 0 | 0 | 277 | 2 | 1 | 87 | 291 | 357 | 239 | 425 | 601 | 1,226 |
| 415 | 523 | 585 | 1,367 | 1,558 | 1,676 | 2,043 | 2,227 | 2,628 | 2,351 | 2,819 | 2,690 | |
| Total Assets | 466 | 576 | 922 | 1,644 | 1,846 | 2,093 | 2,658 | 3,009 | 3,368 | 3,287 | 3,930 | 4,434 |
Cash Flows
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 4 | 52 | -21 | 49 | 75 | 222 | 424 | 223 | 389 | 756 | 459 | 443 | |
| -8 | -5 | -289 | -40 | -35 | -118 | -282 | -281 | -327 | -426 | -404 | -329 | |
| 0 | -0 | 276 | 7 | -65 | -61 | -47 | -63 | -73 | -331 | -66 | -81 | |
| Net Cash Flow | -4 | 47 | -34 | 16 | -26 | 43 | 95 | -120 | -10 | -1 | -11 | 33 |
| Free Cash Flow | -6 | 44 | -310 | 6 | 36 | 184 | 382 | 111 | 270 | 695 | 432 | 404 |
| CFO/OP | 44% | 102% | 14% | 60% | 56% | 90% | 109% | 61% | 83% | 187% | 100% | 91% |
Ratios
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 83 | 92 | 101 | 105 | 110 | 128 | 117 | 101 | 98 | 91 | 90 | 81 |
| Inventory Days | 135 | 169 | 191 | 202 | 193 | 133 | 185 | 198 | 157 | 135 | 154 | 149 |
| Days Payable | 109 | 132 | 115 | 176 | 136 | 112 | 145 | 110 | 87 | 96 | 107 | 77 |
| Cash Conversion Cycle | 109 | 130 | 177 | 131 | 167 | 150 | 157 | 189 | 168 | 131 | 136 | 153 |
| Working Capital Days | 69 | 79 | 113 | 113 | 116 | 109 | 95 | 127 | 136 | 173 | 183 | 256 |
| ROCE % | 27% | 41% | 22% | 29% | 27% | 26% | 33% | 34% | 30% | 21% | 25% | 23% |
Insights
In beta| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|
| Number of Dealers Number |
|
|||||
| Number of Depots Number |
||||||
| Number of Direct Distributors Number |
||||||
| Number of Patents Granted Number |
||||||
| Number of Permanent Employees Number |
||||||
| Number of Brands Number |
||||||
| Number of SKUs Number |
||||||
| Meshi Product Volume (Launch Year) Lakh Litres |
||||||
Extracted by Screener AI
Documents
Announcements
-
Integrated Filing (Financial) For The Quarter And Year Ended 31St March, 2026.
11 Jun - FY26 audited standalone/consolidated results released; board declares ₹1.3 per share dividend, subject to AGM approval.
-
Announcement under Regulation 30 (LODR)-Earnings Call Transcript
4 Jun - Written transcript of earnings call held on 28th May, 2026
-
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome
28 May - Earnings call scheduled for 28 May 2026 at 2:00 pm to discuss FY26 results.
-
Announcement under Regulation 30 (LODR)-Investor Presentation
27 May - Investor Presentation for the quarter and year ended 31st March, 2026
-
Announcement under Regulation 30 (LODR)-Change in Management
26 May - Dr. Suresh Ramachandran promoted to Managing Director from 1 September 2026, subject to shareholder approval.
Annual reports
Concalls
-
Jun 2026Transcript PPT
-
Jan 2026TranscriptAI SummaryPPT
-
Jan 2026TranscriptAI SummaryPPT
-
Nov 2025Transcript PPT REC
-
Aug 2025TranscriptAI SummaryPPT
-
Jun 2025Transcript PPT
-
Jan 2025TranscriptAI SummaryPPT
-
Nov 2024Transcript PPT
-
Jul 2024TranscriptAI SummaryPPT
-
Jun 2024Transcript PPT
-
Feb 2024TranscriptAI SummaryPPT
-
Nov 2023Transcript PPT
-
Aug 2023TranscriptAI SummaryPPT
-
May 2023Transcript PPT
-
Feb 2023TranscriptAI SummaryPPT
-
Nov 2022Transcript PPT
-
Aug 2022TranscriptAI SummaryPPT
-
Aug 2022TranscriptAI SummaryPPT
-
Jun 2022Transcript PPT REC
-
Feb 2022TranscriptAI SummaryPPT
-
Nov 2021Transcript PPT
-
Aug 2021TranscriptAI SummaryPPT
-
Jun 2021Transcript PPT
-
Feb 2021TranscriptAI SummaryPPT
-
Nov 2020Transcript PPT
-
Aug 2020TranscriptAI SummaryPPT
-
Jun 2020TranscriptAI SummaryPPT
-
Feb 2020TranscriptAI SummaryPPT
Products
The company operates in agorchemicals, including insecticides, weedicides, fungicides, fumigants, rodenticides, plant growth nutrition products, bio-rationals, and plant growth regulators. It markets proprietary products from its Japanese parent, Sumitomo Chemical Co., in agrochemicals, animal nutrition, and environmental health.[1]
The products comprise conventional chemistry sourced from SCC, and biological products sourced from a USA-based subsidiary, Valent Biosciences LLC. [2]